Edition:
United Kingdom

Zealand Pharma A/S (ZELA.CO)

ZELA.CO on Copenhagen Stock Exchange

130.00DKK
11:30am BST
Change (% chg)

kr.1.80 (+1.40%)
Prev Close
kr.128.20
Open
kr.129.00
Day's High
kr.130.40
Day's Low
kr.128.50
Volume
140,555
Avg. Vol
162,701
52-wk High
kr.131.20
52-wk Low
kr.78.60

Latest Key Developments (Source: Significant Developments)

Zealand Pharma Announces Emmanuel Dulac As New CEO
Friday, 5 Apr 2019 

April 5 (Reuters) - Zealand Pharma A/S ::ZEALAND PHARMA ANNOUNCES EMMANUEL DULAC AS NEW CEO.EMMANUEL DULAC WILL JOIN ZEALAND PHARMA AS NEW CHIEF EXECUTIVE OFFICER ON APRIL 22, 2019.EMMANUEL COMES FROM A POSITION AS CHIEF COMMERCIAL OFFICER AT ALNYLAM PHARMACEUTICALS.  Full Article

Zealand Pharma A/S Files For Mixed Shelf Of Upto $200 Mln
Monday, 1 Apr 2019 

April 1 (Reuters) - Zealand Pharma A/S ::ZEALAND PHARMA A/S FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING.  Full Article

Zealand Pharma: Alexion Pharmaceuticals To Invest USD 15 Mln In Co
Wednesday, 20 Mar 2019 

March 20 (Reuters) - Zealand Pharma A/S ::AS PART OF AGREEMENT, ALEXION PHARMACEUTICALS WILL INVEST USD 15 MILLION IN ZEALAND TO SUBSCRIBE FOR 802,859 NEW SHARES.  Full Article

Alexion And Zealand Pharma Announce Pact To Discover And Develop Peptide Therapies
Wednesday, 20 Mar 2019 

March 20 (Reuters) - Alexion Pharmaceuticals Inc ::ALEXION AND ZEALAND PHARMA ANNOUNCE COLLABORATION TO DISCOVER AND DEVELOP PEPTIDE THERAPIES FOR COMPLEMENT-MEDIATED DISEASES.ZEALAND PHARMA A/S - COLLABORATION FURTHERS ALEXION'S COMPLEMENT LEADERSHIP WITH EXPANSION INTO PEPTIDE THERAPIES.ZEALAND-AGREEMENT PROVIDES ALEXION EXCLUSIVE WORLDWIDE LICENSES FOR 1 PRECLINICAL TARGET, OPTION FOR UP TO 3 ADDITIONAL TARGETS, IN COMPLEMENT PATHWAY.ZEALAND - TO RECEIVE UPFRONT PAYMENT OF $25 MILLION & EQUITY INVESTMENT OF $15 MILLION, WITH POTENTIAL FOR ADDITIONAL MILESTONE-DEPENDENT & ROYALTY PAYMENTS.ZEALAND PHARMA A/S - WILL LEAD JOINT DISCOVERY AND RESEARCH EFFORTS THROUGH PRECLINICAL STAGE.ZEALAND PHARMA A/S - ALEXION WILL LEAD DEVELOPMENT EFFORTS BEGINNING WITH IND FILING AND PHASE 1 STUDIES.ZEALAND PHARMA A/S - FOR LEAD TARGET, AGREEMENT PROVIDES POTENTIAL FOR DEVELOPMENT-RELATED MILESTONES OF UP TO $115 MILLION.ZEALAND-FOR LEAD TARGET AGREEMENT PROVIDES UP TO $495 MILLION IN SALES-RELATED MILESTONES, POTENTIAL FOR HIGH SINGLE- TO LOW DOUBLE-DIGIT ROYALTY PAYMENTS.  Full Article

Zealand Pharma Announces Full-Year 2018 Results
Thursday, 7 Mar 2019 

March 7 (Reuters) - Zealand Pharma A/S ::REG-ZEALAND PHARMA ANNOUNCES FULL-YEAR 2018 RESULTS, STRONG CASH POSITION TO SUPPORT PIPELINE PROGRESS.NET OPERATING EXPENSES IN 2019 ARE EXPECTED TO BE WITHIN DKK 550-570 MILLION.FY REVENUE OF DKK 38.0 MILLION, DOWN 72 PERCENT YOY.FY OPERATING PROFIT DKK 652.4 MILLION VERSUS LOSS DKK 249.4 MILLION YEAR AGO.NO DIVIDEND HAS BEEN PROPOSED.  Full Article

Zealand Pharma Says CFO Mats Blom Will Leave Zealand at End of March 2019
Wednesday, 23 Jan 2019 

Jan 23 (Reuters) - Zealand Pharma A/S ::REG-CHANGES TO ZEALAND PHARMA’S EXECUTIVE MANAGEMENT.BOARD OF DIRECTORS HAS DECIDED THAT BRITT WILL BE RELEASED FROM HER DUTIES AS PRESIDENT AND CEO AS OF 28 FEBRUARY 2019.SAYS MATS BLOM, CHIEF FINANCIAL OFFICER, WILL LEAVE ZEALAND END MARCH 2019..SEARCH FOR A NEW CFO HAS BEEN INITIATED.BOARD INITIATED AN INTERNATIONAL SEARCH FOR A NEW PRESIDENT AND CEO END NOVEMBER 2018.  Full Article

Zealand Pharma Q3 Operating Profit Up At DKK 1.01 Billion
Thursday, 15 Nov 2018 

Nov 15 (Reuters) - Zealand Pharma A/S ::REG-ZEALAND PHARMA - INTERIM REPORT FOR THE FIRST NINE MONTHS OF 2018.MAINTAINS ITS FINANCIAL GUIDANCE FOR FULL-YEAR 2018 AS ANNOUNCED IN COMPANY'S 2017 ANNUAL REPORT..Q3 OPERATING PROFIT DKK 1.01 BILLION VERSUS OPERATING LOSS DKK 39.1 MILLION YEAR AGO.  Full Article

Zealand Pharma Achieves Primary And Key Secondary Endpoints In Pivotal Phase 3 Trial With Dasiglucagon For Severe Hypoglycemia
Tuesday, 18 Sep 2018 

Sept 18 (Reuters) - Zealand Pharma A/S ::REG-ZEALAND PHARMA ACHIEVES PRIMARY AND KEY SECONDARY ENDPOINTS IN PIVOTAL PHASE 3 TRIAL WITH DASIGLUCAGON FOR SEVERE HYPOGLYCEMIA.99% OF PATIENTS ON DASIGLUCAGON RECOVERED FROM LOW BLOOD GLUCOSE WITHIN 15 MINUTES.SAYS WILL SOON INITIATE PHASE 3 TRIAL IN PEDIATRIC DIABETES PATIENTS, WHICH IS EXPECTED TO COMPLETE IN MID-2019.  Full Article

Zealand Sells Royalty Streams And Milestones For $205 Mln To Royalty Pharma
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - Zealand Pharma A/S ::REG-ZEALAND SELLS ROYALTY STREAMS AND MILESTONES FOR USD 205 MILLION TO ROYALTY PHARMA.ZEALAND WILL REMAIN ELIGIBLE FOR A PAYMENT FROM SANOFI UP TO USD 15 MILLION, EXPECTED IN 2020.ZEALAND - TO SELL FUTURE ROYALTY STREAMS, $85 MILLION OF POTENTIAL COMMERCIAL MILESTONES FOR SOLIQUA 100/33/ SULIQUA, LYXUMIA/ADLYXIN TO ROYALTY PHARMA.  Full Article

Zealand Pharma Q2 Operating Loss Widens To DKK 131.9 Million
Thursday, 16 Aug 2018 

Aug 16 (Reuters) - Zealand Pharma A/S ::REG-ZEALAND PHARMA - INTERIM REPORT FOR THE FIRST HALF OF 2018.H1 REVENUE OF DKK 24.9 MILLION / USD 3.9 MILLION (DKK 86.7 MILLION / USD 13.3 MILLION IN FIRST HALF OF 2017.Q2 OPERATING LOSS DKK 131.9 MILLION VERSUS OPERATING LOSS DKK 95.5 MILLION YEAR AGO.  Full Article